[go: up one dir, main page]

HRP20220903T1 - SELADELPAR FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS - Google Patents

SELADELPAR FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS Download PDF

Info

Publication number
HRP20220903T1
HRP20220903T1 HRP20220903TT HRP20220903T HRP20220903T1 HR P20220903 T1 HRP20220903 T1 HR P20220903T1 HR P20220903T T HRP20220903T T HR P20220903TT HR P20220903 T HRP20220903 T HR P20220903T HR P20220903 T1 HRP20220903 T1 HR P20220903T1
Authority
HR
Croatia
Prior art keywords
compound
seladelpar
treatment
primary biliary
biliary cholangitis
Prior art date
Application number
HRP20220903TT
Other languages
Croatian (hr)
Inventor
Pol Boudes
Charles A. Mcwherter
Original Assignee
Cymabay Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics, Inc. filed Critical Cymabay Therapeutics, Inc.
Publication of HRP20220903T1 publication Critical patent/HRP20220903T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (5)

1. Spoj, naznačen time, da je to seladelpar ili njegova sol za uporabu u liječenju primarnog bilijarnog kolangitisa, pri čemu se spoj primjenjuje oralno u jednoj dozi od 5 – 10 mg/dan, kada se doza računa kao seladelpar.1. A compound, characterized in that it is seladelpar or its salt for use in the treatment of primary biliary cholangitis, wherein the compound is administered orally in a single dose of 5-10 mg/day, when the dose is calculated as seladelpar. 2. Spoj za uporabu prema patentnom zahtjevu 1, naznačen time, da spoj jest sol seladelpar L-lizin dihidrata.2. Compound for use according to claim 1, characterized in that the compound is a salt of seladelpar L-lysine dihydrate. 3. Spoj za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time, da se spoj primjenjuje u jednoj dozi od 5 mg/dan.3. Compound for use according to claim 1 or 2, characterized in that the compound is administered in a single dose of 5 mg/day. 4. Spoj za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time, da se spoj primjenjuje u jednoj dozi od 10 mg/dan,4. Compound for use according to patent claim 1 or 2, characterized in that the compound is administered in a single dose of 10 mg/day, 5. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da se spoj daje jednom na dan.5. The compound for use according to any one of claims 1 to 4, characterized in that the compound is administered once a day.
HRP20220903TT 2016-05-31 2017-04-26 SELADELPAR FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS HRP20220903T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31
EP17722943.2A EP3463328B1 (en) 2016-05-31 2017-04-26 Seladelpar for the treatment of primary biliary cholangitis
PCT/US2017/029620 WO2017209865A1 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestatic diseases

Publications (1)

Publication Number Publication Date
HRP20220903T1 true HRP20220903T1 (en) 2022-10-14

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220903TT HRP20220903T1 (en) 2016-05-31 2017-04-26 SELADELPAR FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS

Country Status (27)

Country Link
US (5) US10272058B2 (en)
EP (1) EP3463328B1 (en)
JP (1) JP7079735B2 (en)
KR (1) KR102408288B1 (en)
CN (1) CN109195594A (en)
AU (1) AU2017274293B2 (en)
BR (1) BR112018074147A2 (en)
CA (1) CA3024155C (en)
CY (1) CY1125465T1 (en)
DK (1) DK3463328T3 (en)
ES (1) ES2921230T3 (en)
HR (1) HRP20220903T1 (en)
HU (1) HUE059838T2 (en)
IL (1) IL263372B2 (en)
LT (1) LT3463328T (en)
MX (1) MX390417B (en)
NZ (1) NZ748721A (en)
PL (1) PL3463328T3 (en)
PT (1) PT3463328T (en)
RS (1) RS63345B1 (en)
RU (1) RU2765460C2 (en)
SG (1) SG11201810123SA (en)
SI (1) SI3463328T1 (en)
SM (1) SMT202200471T1 (en)
UA (1) UA122719C2 (en)
WO (1) WO2017209865A1 (en)
ZA (1) ZA201808360B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN106102734B (en) 2014-03-20 2019-05-14 西玛贝医药公司 Treatment of intrahepatic cholestatic disease
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
BR112021009038A2 (en) * 2018-11-16 2021-08-10 Cymabay Therapeutics, Inc. nafld and nash combined treatment
HRP20240660T1 (en) 2021-02-01 2024-08-16 Cymabay Therapeutics, Inc. TREATMENT OF CHOLANGIOPATHY WITH SELADELPAR

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
JPH10512894A (en) 1995-03-06 1998-12-08 アイシス・ファーマシューティカルス・インコーポレーテッド Improved method for the synthesis of 2'-O-substituted pyrimidines and their oligomeric compounds
EP0882061B1 (en) 1996-02-14 2004-05-19 Isis Pharmaceuticals, Inc. Sugar-modified gapped oligonucleotides
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
DK1667964T3 (en) 2003-09-19 2009-10-26 Janssen Pharmaceutica Nv 4 - ((Phenoxyalkyl) thio) -phenoxyacetic acids and analogs
CA2910191C (en) 2004-03-05 2022-03-08 The Trustees Of The Univeristy Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
JO3006B1 (en) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv Novel Lysine Salts of 4-((Phenoxy Alkyl)Thio)-Phenoxy Acetic Acid Derivatives
MX2011004077A (en) 2008-10-17 2011-08-17 Metabolex Inc Methods of reducing small, dense ldl particles.
WO2010127099A2 (en) * 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PH12012501859A1 (en) 2010-03-30 2013-01-07 Novartis Ag Uses of dgat1 inhibitors
JOP20200043A1 (en) 2011-05-10 2017-06-16 Amgen Inc Ways to treat or prevent cholesterol disorders
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
JP2017505285A (en) 2013-11-20 2017-02-16 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Treatment of homozygous familial hypercholesterolemia
CN106102734B (en) 2014-03-20 2019-05-14 西玛贝医药公司 Treatment of intrahepatic cholestatic disease
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR102374499B1 (en) 2014-04-11 2022-03-14 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Treatment of nafld and nash
JP2017519028A (en) 2014-06-26 2017-07-13 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Treatment of severe hypertriglyceridemia
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US20190105291A1 (en) 2017-09-26 2019-04-11 Cymabay Therapeutics, Inc. Treatment of cholestatic pruritus
BR112021009038A2 (en) 2018-11-16 2021-08-10 Cymabay Therapeutics, Inc. nafld and nash combined treatment
EP3880187A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications

Also Published As

Publication number Publication date
BR112018074147A2 (en) 2019-03-06
DK3463328T3 (en) 2022-07-04
US11000494B2 (en) 2021-05-11
WO2017209865A1 (en) 2017-12-07
HUE059838T2 (en) 2023-01-28
LT3463328T (en) 2022-08-10
US10813895B2 (en) 2020-10-27
SMT202200471T1 (en) 2023-01-13
KR20190015363A (en) 2019-02-13
MX390417B (en) 2025-03-20
SI3463328T1 (en) 2022-08-31
IL263372B2 (en) 2023-06-01
KR102408288B1 (en) 2022-06-10
UA122719C2 (en) 2020-12-28
CN109195594A (en) 2019-01-11
PL3463328T3 (en) 2022-10-03
US20200061006A1 (en) 2020-02-27
ZA201808360B (en) 2020-02-26
SG11201810123SA (en) 2018-12-28
CA3024155A1 (en) 2017-12-07
AU2017274293B2 (en) 2022-03-31
ES2921230T3 (en) 2022-08-22
US20190255004A1 (en) 2019-08-22
US20210220305A1 (en) 2021-07-22
RU2018146504A3 (en) 2020-07-27
IL263372A (en) 2018-12-31
US10478411B2 (en) 2019-11-19
RU2765460C2 (en) 2022-01-31
NZ748721A (en) 2022-04-29
US10272058B2 (en) 2019-04-30
EP3463328A1 (en) 2019-04-10
EP3463328B1 (en) 2022-06-15
JP7079735B2 (en) 2022-06-02
US20170340589A1 (en) 2017-11-30
RU2018146504A (en) 2020-07-09
JP2019518022A (en) 2019-06-27
CY1125465T1 (en) 2025-05-09
CA3024155C (en) 2023-10-10
MX2018014915A (en) 2019-04-24
US20210000774A1 (en) 2021-01-07
US11596614B2 (en) 2023-03-07
AU2017274293A1 (en) 2018-12-13
PT3463328T (en) 2022-07-07
RS63345B1 (en) 2022-07-29

Similar Documents

Publication Publication Date Title
HRP20220903T1 (en) SELADELPAR FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS
HRP20210529T1 (en) Mk2 inhibitors and uses thereof
HRP20250022T1 (en) Treatment of cholestatic pruritus with seladelpar
HRP20192202T1 (en) Acc inhibitors and uses thereof
HRP20241039T1 (en) A SUBSTITUTED DERIVATIVE OF POLYCYCLIC PYRIDONE AND ITS PRE-DRUG
HRP20241239T1 (en) Novel heterocyclic derivatives useful as shp2 inhibitors
HRP20230222T1 (en) Prodrug modulators of the integrated stress pathway
FI3355889T3 (en) Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
HRP20221158T1 (en) Apoptosis-inducing agents
HRP20220759T1 (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
HRP20240218T1 (en) MODULATORS OF THE INTEGRATED STRESS PATHWAY
WO2016064082A3 (en) Novel aminoalkyl benzothiazepine derivative and use thereof
IL253595A0 (en) A salt of the compound pyrimido [1,6-a]isoquinolin-4-one
MX2016007522A (en) Sgc stimulators.
MX2018001990A (en) Compositions comprising a pi3k inhibitor and an hdac inhibitor.
CL2014000311A1 (en) Compounds derived from substituted benzothiazepines; pharmaceutical composition that contains them; and its use for the treatment or prophylaxis of respiratory syncytial virus infection.
UY37879A (en) BISAMIDE COMPOUNDS THAT ACTIVATE THE SARCOMERO AND ITS USES
SV2018005682A (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
MX375068B (en) A GROUP OF COMPOUNDS USED FOR THE TREATMENT OR PREVENTION OF HYPERURICEMIA OR GOUT.
PH12015501940B1 (en) Dihydropyridazine-3,5-dione derivative
EP3449001A4 (en) INHIBITION OF ARNMI MIR-22 BY APT-110
HRP20240166T1 (en) Method of treating prader-willi syndrome
HRP20230523T1 (en) ANTI-TUMOR AGENT AND AGENT FOR IMPROVING ANTI-TUMOR EFFECT
HRP20192235T1 (en) COMPOUNDS USEFUL FOR INHIBITING ROR-γ-T
BR112016007462A2 (en) anti-inflammatory phytonutrients for use in the treatment or prevention of synovitis